Relevant BNF section: 220.127.116.11
Last year, we concluded that topical fusidic acid should be first-line treatment for impetigo.1 Since then, ▼retapamulin ointment (Altargo – GlaxoSmithKline), a new antibacterial, has been licensed in the European Union as a short-term treatment for impetigo and infected small lacerations, abrasions or sutured wounds in people aged 9 months or above.2 Advertisements claim that the product “treats localised impetigo in just 5 days”;3 by comparison, the British National Formulary (BNF) advises a 7-day course of fusidic acid.4 Here we consider the place of retapamulin in impetigo and its other licensed indications.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.